06/08/2021 – AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders Download PDF Post navigationPreviousPrevious post:Results from Phase 3 AB09004 study on Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)NextNext post:Publication of a pathogenic mechanism triggered by mast cells in the ALS spinal cord that can be targeted by masitinibRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virusNovember 29, 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemiaNovember 22, 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALSNovember 18, 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)October 18, 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)October 4, 2021Revenues for the first half of 2021 and update on AB Science’s activitiesSeptember 30, 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virusNovember 29, 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemiaNovember 22, 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALSNovember 18, 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)October 18, 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)October 4, 2021
